title: The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
abstract: BACKGROUND
  Major advances have been made in the understanding of the pathophysiology of psoriasis.
  
  
  OBJECTIVE
  The authors review the role of interleukin (IL) 17 in the pathogenesis of psoriasis and provide updates on approved and investigational therapies targeting IL-17 and the IL-17 receptor.
  
  
  METHODS
  A PubMed search was performed for relevant literature.
  
  
  CONCLUSIONS
  The IL-23/Th17 signaling pathway (including IL-17) plays a central role in the pathogenesis of psoriasis. Biologic agents that block IL-17 (secukinumab and ixekizumab) or its receptor (brodalumab) are effective and safe for the treatment of psoriasis.
authors.affiliation: Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Center and University of Toronto, Toronto, ON, Canada derm.moe@gmail.com.
authors.forename: Mohn'd
authors.initials: M
authors.lastname: AbuHilal
authors.affiliation: Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Center and University of Toronto, Toronto, ON, Canada.
authors.forename: Scott
authors.initials: S
authors.lastname: Walsh
authors.affiliation: Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Center and University of Toronto, Toronto, ON, Canada.
authors.forename: Neil
authors.initials: N
authors.lastname: Shear
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D020381:Interleukin-17 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D053759:Interleukin-23 / Q000378:metabolism; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D053722:Receptors, Interleukin-17 / Q000037:antagonists & inhibitors*; D015398:Signal Transduction; D058504:Th17 Cells
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D020381:Interleukin-17; D053759:Interleukin-23; D053722:Receptors, Interleukin-17; C571216:brodalumab; C549079:ixekizumab; C555450:secukinumab
keywords: IL-17; brodalumab; ixekizumab; psoriasis; secukinumab